跳至主要内容
临床试验/2023-507732-20-00
2023-507732-20-00招募中3 期

A randomized double blind, multicenter trial to assess time-interval between cytoreductive surgery and adjuvant chemotherapy after administration of local anesthetic intraperitoneally/perioperatively in advanced epithelial ovarian cancer - IPLA-OVCA

Karolinska University Hospital, Karolinska University Hospital2 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2023年8月30日最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
220
试验地点
2
主要终点
Time (days) to start of adjuvant chemotherapy after cytoreductive surgery

研究概览

简要总结

To investigate whether Ropivacaine 0.2% administered intraperitoneally during surgery and intermittently thereafter for up to 72 h in patients with stage III-IV epithelial ovarian cancer undergoing cytoreductive surgery leads to earlier start of adjuvant chemotherapy.

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
性别
Female
接受健康志愿者

入选标准

  • Women > 18 years
  • Scheduled for upfront cytoreductive surgery for stage III or IV epithelial ovarian cancer
  • Signed written informed consent

排除标准

  • Contraindication to epidural anesthesia
  • Allergy to any component drugs used during epidural or intraperitoneal anesthesia (Ropivacaine, Sufentanil)
  • Uncontrolled renal, liver, heart failure or ischemic heart disease
  • Speech, language or cognitive difficulties
  • Women in whom cytoreductive surgery is not attempted at time of upfront laparotomy due to extent of disease

结局指标

主要结局

Time (days) to start of adjuvant chemotherapy after cytoreductive surgery

Time (days) to start of adjuvant chemotherapy after cytoreductive surgery

次要结局

  • Postoperative complications, postoperative morbidity, quality of recovery, cardiac and renal impairment and overall survival

研究者

发起方
Karolinska University Hospital, Karolinska University Hospital
申办方类型
Hospital/Clinic/Other health care facility, Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Sponsor representative

Scientific

Karolinska University Hospital

研究点 (2)

Loading locations...

相似试验